The 4th EMN meeting will take place from 20 unil 22 April 2023 at the Beurs van Berland in Amsterdam, The Netherlands.
This is a save-the-date!
More information about the participation of the HARMONY Alliance to follow.
More information about EMN2023, click here >
Multiple myeloma is a rare and highly heterogeneous hematologic malignancy, and the clinical research certainly plays a fundamental role in the management of patients with this disease. To deal with such a complex scenario, in 2005, a group of European hematologists pulled together to increase their understanding of multiple myeloma and to produce effective research projects and clinical trials. These efforts resulted in the creation of the European Myeloma Network (EMN), a non profit organization. EMN is a HARMONY Partner. An important Multiple Myeloma project is being coordinated by the EMN within HARMONY, and it involves many European sites.
Read here the latest HARMONY Alliance press release about the Multiple Myeloma Research Result : Proposed revision of staging system for Multiple Myeloma by Mattia D'Agostino >
#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.
Receive the latest news. Click here to subscribe!
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Login
